New drug could offer stroke survivors better outcomes

Image
Press Trust of India London
Last Updated : Feb 26 2015 | 4:35 PM IST
A new cheaper, safer and easy to administer drug treatment for ischaemic stroke patients has passed first clinical tests with promising results, scientists said.
The new treatment, Tenecteplase, is said to have similar outcomes in limiting the damage done in the brain after a stroke compared with current treatments, it is also far easier to administer and may also be safer, they said.
The results for the new drug treatment were published today in the journal 'Lancet Neurology'.
Crucially however, it is also far easier to administer and may also be safer.
Ischaemic strokes are caused by a blood clot blocking a blood vessel in the brain, and are treated by injecting 'clot-busting' drugs that dissolve the blood clot, restoring blood flow.
There is a four and a half hour window after an ischaemic stroke in which giving clot-busting drug treatment is effective in limiting damage and improving outcome.
Currently, only one drug - Alteplase - is used for acute treatment of stroke.
The study, led by Professor Keith Muir, SINAPSE Chair of Clinical Imaging and Consultant Neurologist at the University of Glasgow, compared Alteplase with a newer clot-busting drug called Tenecteplase.
The study, funded by the Stroke Association, showed that incidences of serious adverse events did not differ between the two groups and all neurological and radiological outcomes were similar, despite there being slightly more very severe strokes in the Tenecteplase group.
The results also showed that potentially fewer people had a brain haemorrhage as a complication of treatment with Tenecteplase.
Researchers believe that, as Tenecteplase can be given more easily than Alteplase, it could become a less expensive and easier to administer treatment for ischaemic stroke patients.
However, a larger clinical trial will be needed in the lab to test Tenecteplase fully, and plans for such a trial are at an advanced stage.
Professor Muir said: "Every minute is crucial in treating stroke and we need better treatment options. Any treatment that is easier to deliver and potentially safer could mean the difference between a good recovery and someone suffering serious debilitating long term effects.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 26 2015 | 4:35 PM IST

Next Story